Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

An antimicrobial peptide of the cathelicidin family that provides innate immune defense by killing pathogens and modulating inflammation and wound healing.

Quick Stats
Studies 2230
Trials 95
Formula C205H340N60O53
Clear All
Utility 1
pubmed Sep 27, 2023

Glycine fermentation by <i>C. difficile</i> promotes virulence and spore formation, and is induced by host cathelicidin.

Rizvi. Arshad A; Vargas-Cuebas. Germ&#xe1;n G; Edwards. Adrianne N AN; DiCandia. Michael A MA; Carte...

The research shows that the gut bug Clostridioides difficile uses the amino acid glycine for energy, and a natural immune peptide called LL‑37 from the host can turn on this pathway, making the bacteria grow faster, produce more toxin, and form more spores, which worsens infection.

Utility 1
pubmed Jan 19, 2024

Etiopathogenesis of Psoriasis: Integration of Proposed Theories.

Hernandez-Nicols. Brenda Fernanda BF; Robledo-Pulido. Juan Jos&#xe9; JJ; Alvarado-Navarro. Anabell A

The review explains why psoriasis happens, focusing on three ideas: the body’s own antimicrobial peptide LL‑37 can act like an auto‑antigen and trigger inflammation, an imbalance of skin microbes may worsen the condition, and too‑much oxidative stress can drive immune pathways that cause skin plaques. It’s mostly basic science, not a how‑to guide for health‑hacking.

Utility 1
pubmed Jan 13, 2025

Human Defence Factors in Different Gestational Week Placenta: A Pilot Study.

Kamergrauzis. Andris A; Pilmane. Mara M; Junga. Anna A

The study looked at how the antimicrobial peptide LL‑37 and other immune proteins are present in human placenta at different stages of pregnancy. LL‑37 was only found in a type of placental macrophage (Hofbauer cells) and its amount increased as the pregnancy progressed. Other defence proteins also rose with gestational age, showing a coordinated immune network in the placenta.

Utility 1
pubmed Nov 13, 2023

Deciphering Solution and Gas-Phase Interactions between Peptides and Lipids by Native Mass Spectrometry.

Kundlacz. Til T; Schmidt. Carla C

The study looked at how the antimicrobial peptide LL‑37 sticks to different fats (lipids) using a technique called native mass spectrometry, which moves the molecules into the gas phase. It found that the strength of the electric (electrostatic) attractions shows up well in the gas‑phase data, while the water‑fearing (hydrophobic) attractions mainly affect how strong the signal is, not how stable the complex is in the gas. This means the method can tell you about some types of binding but not all, especially the ones that matter in the body’s watery environment.

Utility 1
pubmed Feb 10, 2024

Current Approach to Risk Factors and Biomarkers of Intestinal Fibrosis in Inflammatory Bowel Disease.

Dudek. Patrycja P; Talar-Wojnarowska. Renata R

The paper talks about how people with inflammatory bowel disease (IBD) can develop scar tissue in their intestines, which makes the disease worse. Researchers are looking for easy‑to‑measure signs in the blood that show when this scarring is happening. One of the possible signs is a protein called LL‑37, but the study only mentions it as a marker, not as something you can take or change yourself.

Utility 1
pubmed Mar 7, 2025

Effects of Surface Charge of Amphiphilic Peptides on Peptide-Lipid Interactions in the Gas Phase and in Solution.

Kundlacz. Til T; Schwieger. Christian C; Schmidt. Carla C

The study shows that the electric charge on the surface of the antimicrobial peptide LL‑37 and its variants determines how well they stick to different fats (lipids). Positive or negative charges on the peptide make it bind more strongly to lipids with the opposite charge, and the wild‑type peptide is the most flexible in forming these bonds. The researchers used special lab techniques to see these interactions both in the gas phase and in liquid.

Utility 1
pubmed Sep 14, 2024

Thermodynamic Study on Biomimetic <i>Legionella gormanii</i> Bacterial Membranes.

Pastuszak. Katarzyna K; Palusi&#x144;ska-Szysz. Marta M; Wi&#x105;cek. Agnieszka Ewa AE; Jurak. Ma&#...

Researchers looked at how a human antimicrobial peptide called LL‑37 interacts with thin layers that mimic the membranes of a bacteria called Legionella. They found that when the bacteria were grown with choline, the membrane lipids behaved differently and were more attractive to each other, while LL‑37 made the membrane layers less stable. The peptide’s effect changed depending on whether choline was present during bacterial growth.

Utility 1
pubmed Jul 25, 2024

Antileishmanial Activity of Cathelicidin and its Modulation by Leishmania donovani in a cAMP Response Element Modulator-Dependent Manner in Infection.

Roy. Shalini S; Roy. Souravi S; Banerjee. Madhurima M; Madbhagat. Pratibha P; Chande. Ajit A; Ukil....

The study shows that the human antimicrobial peptide LL‑37 can kill the parasite that causes visceral leishmaniasis, but the infection blocks the body’s own production of LL‑37 by turning off the vitamin‑D receptor and turning on a repressor called CREM. Silencing CREM in cells or mice helps clear the parasite, but the work is done in lab cells and mice, not people.

Utility 1
pubmed Apr 12, 2024

Levels of Lysozyme and SLPI in Bronchoalveolar Lavage: Exploring Their Role in Interstitial Lung Disease.

Osuna-G&#xf3;mez. Rub&#xe9;n R; Mulet. Maria M; Barril. Silvia S; Cant&#xf3;. Elisabet E; Millan-Bil...

The study found that people with lung scarring (fibrotic ILD) have lower levels of natural antimicrobial proteins like lysozyme, SLPI, and LL‑37 in their lung fluid, and these low levels are linked to higher levels of fibrosis‑promoting signals. While the proteins seem to help fight fibrosis, the research doesn’t give any clear ways to use them for health hacks or dosing advice.

Utility 1
pubmed Jan 6, 2024

Association between dysbiotic perio-pathogens and inflammatory initiators and mediators in COVID-19 patients with diabetes.

Bachtiar. Endang W EW; Bachtiar. Boy M BM; Kusumaningrum. Ardiana A; Sunarto. Hari H; Soeroso. Yunia...

The study looked at people with gum disease who also had COVID‑19, comparing those with and without diabetes. It found that a virus‑entry protein (ACE2) and inflammation signals were linked mainly in the diabetic group, and that a combo of two inflammation markers (IL‑6 and complement C3) could hint at how bad the gum inflammation is. The peptide LL‑37 was measured but didn’t show a clear role.

Utility 1
pubmed Mar 5, 2024

<i>Enterobacterales</i> Biofilm-Specific Genes and Antimicrobial and Anti-Inflammatory Biomarkers in the Blood of Patients with Ischemic Heart Disease.

Giedraitiene. Agne A; Tatarunas. Vacis V; Kaminskaite. Kornelija K; Meskauskaite. Ugne U; Boieva. Sv...

Researchers found bits of bacteria and a protein called LL‑37 in the blood of people with heart disease. The bacterial DNA showed up more often in younger patients and those with diabetes, and higher LL‑37 levels were linked to the presence of these bacteria. This suggests a possible link between gut bacteria, inflammation, and heart problems, but it doesn’t give clear steps you can take right now.

Utility 1
pubmed Feb 1, 2024

Antimicrobial peptides and other potential biomarkers of critical illness in SARS-CoV-2 patients with acute kidney injury. AMPAKI-CoV study.

Theotonio Dos Santos. Lucas Ferreira LF; Barbeiro. Hermes Vieira HV; Barbeiro. Denise Frediani DF; d...

The study measured several antimicrobial peptides, including LL‑37, in COVID‑19 patients with and without kidney injury. It found that other peptides (alpha‑defensins) and inflammatory cytokines were higher in sick patients, but it didn’t show any clear benefit or dosage guidance for LL‑37, so there’s nothing immediately useful for self‑experiments.

Utility 1
pubmed Dec 22, 2022

LL-37 antimicrobial peptide and heterologous prime-boost vaccination regimen significantly induce HIV-1 Nef-Vpr antigen- and virion-specific immune responses in mice.

Nikyar. Arash A; Bolhassani. Azam A; Agi. Elnaz E

Scientists tested a tiny protein called LL-37 as a carrier to help DNA vaccines work better in mice. They found that using LL-37 with a DNA vaccine and a protein boost gave stronger immune responses than DNA alone, even at a lower DNA dose. This work is still early‑stage animal research and not a ready‑to‑use method for people.

Utility 1
pubmed Jun 30, 2023

Antimicrobial Peptide Loss, Except for LL-37, is not Characteristic of Atopic Dermatitis.

Szab&#xf3;. Lilla L; Kapit&#xe1;ny. Anik&#xf3; A; Somogyi. Orsolya O; Alhafez. Iman I; G&#xe1;sp&#xe...

The study found that the skin‑protecting peptide LL‑37 is unusually low in people with atopic dermatitis, both in affected skin and in skin that looks normal, while most other antimicrobial peptides are higher or unchanged. This suggests LL‑37 might be important in the early stages of the disease, but the research doesn’t test any treatments or give direct advice for using the peptide.

Utility 1
pubmed Jul 8, 2023

Bactericidal Activity to <i>Escherichia coli</i>: Different Modes of Action of Two 24-Mer Peptides SAAP-148 and OP-145, Both Derived from Human Cathelicidine LL-37.

&#xd6;n. Ayse A; Vejzovic. Djenana D; Jennings. James J; Parigger. Lena L; Cordfunke. Robert A RA; D...

The study looks at how two lab‑made versions of a natural human peptide (LL‑37) kill E. coli bacteria. It finds that killing isn’t just about poking holes in the bacterial membrane; instead, the peptides disturb the membrane’s electric charge and how its fats are packed, which leads to death. This effect works the same way regardless of the bacteria’s surface sugar coat.

Utility 1
pubmed Jan 9, 2024

Development of a 3D multifunctional collagen scaffold impregnated with peptide LL-37 for vascularised bone tissue regeneration.

Balachandran Megha. Kizhakkepurakkal K; Syama. Santhakumar S; Padmalayathil Sangeetha. Vijayan V; Va...

Scientists made a 3‑D collagen sponge coated with bone‑like mineral and loaded it with the peptide LL‑37. In lab tests it helped bone‑cancer cells turn into bone‑forming cells without killing them, and in rabbits it sped up new bone growth in a leg defect compared to the sponge without the peptide.

Utility 1
pubmed Jan 19, 2023

Cathelicidin LL-37 promotes EMT, migration and metastasis of hepatocellular carcinoma cells in vitro and mouse model.

Zhang. Huidan H; Yuan. Xueli X; Yang. Yaxin Y; Wanyan. Yangke Y; Tao. Liping L; Chen. Yuqing Y

The study found that the natural peptide LL‑37 actually helps liver cancer cells become more aggressive and spread, and it also blocks the anti‑cancer effects of vitamin D. In simple terms, more LL‑37 makes liver cancer worse, while reducing LL‑37 could let vitamin D work better against the disease.

Utility 1
pubmed May 22, 2023

Cathelicidin LL-37 Expression in Human Breast Implant Capsules.

Segreto. Francesco F; Carotti. Simone S; Marangi. Giovanni Francesco GF; Francesconi. Maria M; Calia...

The study found that the immune peptide LL‑37 shows up in cells around breast implants and seems to be linked to less severe scar tissue (capsular contracture). While this hints that LL‑37 could be a marker or target for better implant designs, it doesn’t give any direct advice or dosage for everyday health or performance optimization.

Utility 1
pubmed Mar 13, 2023

Influence of Lipidation Pattern of the KR12 Fragment of Peptide LL-37 on Its Antibacterial and Hemolytic Activities.

Kamysz. El&#x17c;bieta E; Sikorska. Emilia E; Bauer. Marta M; Sikora. Karol K; Neubauer. Damian D

Scientists tweaked a small piece of the natural peptide LL‑37 by adding fatty acid groups in different spots. They found that where and how much they added these groups changed how well the peptide killed bacteria and how much it damaged red blood cells. The most promising version was a version with an octanoic acid at the start, which was good at killing Staph aureus while being less harmful to human cells, especially when the peptide carried a +5 charge.

Utility 1
pubmed Mar 11, 2023

Antibacterial peptides-loaded bioactive materials for the treatment of bone infection.

Wang. Gan G; Cui. Yutao Y; Liu. He H; Tian. Yuhang Y; Li. Shaorong S; Fan. Yi Y; Sun. Shouye S; Wu....

This paper reviews how the natural antimicrobial peptide LL‑37 can be put into special bone‑repair materials to fight infections after fractures. It explains why LL‑37 is good at killing bacteria without quickly causing resistance, and describes ways scientists are loading it onto scaffolds or coatings to keep it stable at the injury site. The article is mostly a theoretical overview, not a new treatment you can try yourself.